In a recent announcement, Porton Advanced revealed that its Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSCs) Cell Bank for exosome production has gained FDA's Center for Biologics Evaluation approval for filing. The news came from Cranbury, N.J. and Suzhou, China on July 8, 2026, through a PRNewswire release. This development highlights a significant step for the company in biologics, with promising implications for the medical field.